U.S., June 12 -- ClinicalTrials.gov registry received information related to the study (NCT07016321) titled 'Emetine for Viral Outbreaks (a.k.a. EVOLVE Antiviral Initiative)' on May 20.
Brief Summary: The goal of this study is to evaluate the efficacy and safety of emetine administered orally for symptomatic patients aged 18-65 years infected with the dengue virus. The main questions it aims to answer are:
1. Does emetine reduce 28-day mortality or progression to severe dengue (severe plasma leakage, severe bleeding, or severe organ involvement)?
2. What are the safety outcomes of emetine, including serious adverse events and toxicities?
Participants will be asked to:
1. Take either 6mg emetine, 12mg emetine, or a placebo pill for 7 co...